We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Mylan Pushes FDA To Rule On Ranbaxy's Lipitor ANDA

Law360, New York (March 21, 2011, 1:57 PM EDT) -- Mylan Pharmaceuticals Inc. is accusing the U.S. Food and Drug Administration of stalling on a decision that could give Ranbaxy Laboratories Ltd. exclusive rights to market a generic version of the cholesterol drug Lipitor, saying the delay could cost patients millions of dollars.

Mylan, which also wants to make a generic version of Lipitor, filed its lawsuit Friday in the U.S. District Court for the District of Columbia. It asks the court to require the FDA to strip India-based Ranbaxy of its eligibility for the exclusive...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.